Linking our results further to future therapy of HER2+ brain metastasis, we showed that DUSP6 knockdown increases sensitivity to tucatinib+trastuzumab+capecitabine combination regimen, which show significant clinical activity in HER2+ breast cancer patients with brain metastasis (Murthy et al, 2020). Here, DUSP6 is linked to breast carcinoma.